TickerTalks
Browse all tickers →
TickerTalks›$GPCR
GPGPCR

Structure Therapeutics Inc.

Rising onWhy it's trendingMoving on elevated volumeHeavy, mixed discussion
$GPCR·$2.1B·Biotechnology·Healthcare
$29.86-4.5%YTD-55.2%1Y+11.7%
Price updated 12m ago·X counts updated 4d ago
GPGPCR
$GPCRStructure Therapeutics Inc.
$29.86-4.51%70 posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $GPCR on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

70X posts · last 7 days
Sep 13Sep 27
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $GPCR's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Mixed sentimentAI analysisGenerated by AI from underlying data25 posts analyzed · as of 2026-09-15

Structure Therapeutics reported oral GLP-1 aleniglipron up to 16.2% mean weight loss at 72 weeks with <5% AE discontinuation, but bears are picking apart the 2.5mg-start Phase 3 dose (only ~9% at 36 weeks), significant vomit rates and ALT liver enzyme elevations at higher doses. Jefferies Buy $125, Clear Street Buy $99 — analyst side stays bullish; KOL takes are dissecting whether this is competitive enough for BP interest.

Read what X is saying about $GPCR

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $GPCR — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventSelling offAI verdict · as of 2026-10-01

Falling on heavy selling — points lower unless it turns around.

Oral GLP-1 obesity data showed up but down ~55% year to date; bears are picking apart Phase 3 dosing details

Structure Therapeutics is a zero-revenue clinical-stage biotech whose entire story is the oral GLP-1 aleniglipron program plus the new amylin agonist ACCG-2671 — any read has to anchor on the data, not the financials.

  • The Sep 8 release showed up to 16.2% mean weight loss at 72 weeks with under 5% adverse-event discontinuation — competitive on both headline metrics against the oral GLP-1 field
  • A new 10%+ beneficial owner filed Form 3 on Aug 7, which is a non-trivial institutional accumulation signal just ahead of the Sep 8 data
  • Operating losses continue — Q2 EPS -$0.49 missed by 25%, 52-week range position just 9% (near the floor), down 55% year to date, and the trailing twelve-month gain is only ~12%

The Nov 5 earnings call will set the next narrative; the pipeline reads can continue running into year-end.

What to watch: Full Phase 3 dose-titration readouts, the Nov 5 earnings call for runway update, and whether the new 10%+ holder adds further.

On the calendar: 2026-11-05 — Q3 2026 earnings

float missingbeta missing

Read the AI verdict on $GPCR

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing an oral GLP-1 receptor agonist (GSBR-1290) for obesity and type 2 diabetes, with additional GPCR pipeline.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $GPCR.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $GPCR

Neutral — Clinical-stage biotech developing an oral GLP-1 receptor agonist (GSBR-1290) for obesity and type 2 diabetes, with additional GPCR pipeline.

Top industry ETF

$IBBiShares Biotechnology ETF
+24.1%YTD
+45.8%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-19.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-14.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-5.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-15.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.49$-0.39-25.6%
Q1 2026May 7, 2026$-0.35$-0.39+10.3%
Q4 2025Feb 26, 2026$-0.49$-0.35-40.0%
Q3 2025Nov 6, 2025$-0.37$-0.36-2.8%
Next earningsThu, Nov 5·consensus EPS $-0.33

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-1.05$14.1M
Q4 FY25$0———$0.60$-65.9M
Q3 FY25$0———$-1.11$-52.6M
Q2 FY25$0———$-1.08$-54.8M

Forward consensus

5-year forecast · up to 11 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$38.5M$38.5M – $38.5M-$1.67-$1.82 – -$1.358
FY27$45K$45K – $45K-$2.15-$2.42 – -$1.8211
FY28$187.7M$187.7M – $187.7M-$1.77-$2.96 – $1.228
FY29$539.5M$539.5M – $539.5M-$0.04-$0.04 – -$0.046
FY30$970.4M$970.4M – $970.4M$1.74$1.74 – $1.746

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.9%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-31.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-42.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 21Coll Crespo BlasCHIEF MEDICAL OFFICER4.0K sh—SellSep 1Xichen LinCHIEF SCIENTIFIC OFFICER5.9K sh—SellAug 18Xichen LinCHIEF SCIENTIFIC OFFICER3.9K sh—SellAug 4Xichen LinCHIEF SCIENTIFIC OFFICER3.9K sh—SellJul 22Llc FmrSee Remark 117.5K sh—SellJul 14Xichen LinCHIEF SCIENTIFIC OFFICER7.9K sh—SellJun 25Xichen LinCHIEF SCIENTIFIC OFFICER7.9K sh—SellApr 14Llc FmrSee Remark 116.1K sh—
+ 20 other (8 awards · 6 conversions · 5 exempts · 1 inkind) in window

See when $GPCR insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDSep 88-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Structure Therapeutics announced positive Phase 1/2a single ascending dose (SAD) results for ACCG-2671 (an oral small molecule amylin receptor agonist) and its oral GLP-1 program for chronic weight management, demonstrating clinical proof-of-concept for oral small molecule approaches to next-generation obesity treatment. The data represent an important competitive development as multiple companies race to develop oral alternatives to injectable GLP-1 drugs like Wegovy and Ozempic. This positions Structure Therapeutics as a potential breakthrough player in the obesity drug market with differentiated oral mechanisms.

3New insider — initial holdingsAug 73
AI summary

A new 10%+ beneficial owner filed a Form 3 initial statement of ownership for GPCR (GPCR) dated 2026-08-07. The filing reports initial beneficial ownership of shares, representing approximately a 10%+ stake of outstanding shares. Form 3 is required within 10 days of crossing the 10% ownership threshold and is an administrative disclosure. This indicates significant insider or institutional accumulation and may precede further Schedule 13D/G activity.

8-KShareholder voteJun 188-K — Item 5.07: Shareholder vote
8-KMaterial agreementMay 78-K — Item 1.01: Material agreement · Item 2.02: Earnings release · Item 8.01: Other event
424B5Prospectus supplement (offering)May 7424B5
AI summary

Structure Therapeutics amended and restated its ATM sales agreement removing the aggregate offering cap, and filed this 424B5 to increase the maximum ATM capacity to $400M aggregate gross; approximately $58.5M (3.04M ADSs) had been sold under the prior agreement, leaving approximately $341.5M remaining capacity. Major ATM upsizing to $400M total; $341.5M remaining represents substantial ongoing dilution potential.

3New insider — initial holdingsApr 233
8-KOfficer or director changeApr 158-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
+ 6 other (2 10-Qs · 1 earnings 8-K · 1 13G · 1 ARS) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Stock Rated “Moderate Buy” by Sell-Side Brokeragesdefenseworld.net·6d agoLLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?zacks.com·14d agoStructure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com·15d agoStructure Therapeutics: The Amylin Data Changes The Mathseekingalpha.com·22d agoStructure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management Transcriptseekingalpha.com·23d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$VKTX$MRNA$RARE$NWBO$AURA$ARCT$IBRX$NKTR
Voices on X · last 7 days

No standout posts about $GPCR on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport